CMed Technologies Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Horsham United Kingdom (2002)

Organization Overview

First Clinical Trial
2010
NCT01218217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cmed | Cmed Clinical Services

Active Ingredients

Drugs in Phase 3 Trials (1)

bupivacaine (Exparel) (1 trial)

Drugs in Phase 2 Trials (3)

nbe-002 (1 trial)

rifampin (1 trial)

sq109 (1 trial)

Drugs in Phase 1 Trials (1)

cpx-pom (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hernia (Phase 3)

Hernia, Inguinal (Phase 3)

Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5